ArticleBrain sciences2021
Interactions of COMT and ALDH2 Genetic Polymorphisms on Symptoms of Parkinson's Disease.
Article in Brain sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Deciphering the Impact of EPHA1-AS1 Gene Polymorphism on Social Cognition Deficits in Parkinson's Disease.CNS neuroscience & therapeutics · 2026Article
- Data-driven characterization of distinct cognitive subtypes in Parkinson's disease dementia.NPJ Parkinson's disease · 2025Article
- Cognitive Impairment-Associated Risk Factors of Parkinson's Disease: A Hospital-Based Study in a Cohort of Upper Egypt Parkinson's Patients.Brain sciences · 2025Article
- A catechol-O-methyltransferase genetic variant impacts functional movement in tactical athletes.PloS one · 2025Article
- The Correlation Between RIN3 Gene Methylation and Cognitive Impairment in Parkinson's Disease.Neuropsychiatric disease and treatment · 2025Article
- Transcranial direct current stimulation for Parkinson's disease: systematic review and meta-analysis of motor and cognitive effects.NPJ Parkinson's disease · 2024Article
- Disgust-specific impairment of facial emotion recognition in Parkinson's disease patients with mild cognitive impairment.Social cognitive and affective neuroscience · 2024Article
- Dopamine in Sports: A Narrative Review on the Genetic and Epigenetic Factors Shaping Personality and Athletic Performance.International journal of molecular sciences · 2024Review
- Brain Glucose Metabolism andDiagnostics (Basel, Switzerland) · 2024Article
- GBA moderates cognitive reserve's effect on cognitive function in patients with Parkinson's disease.Journal of neurology · 2024Article
- Effects of Rehabilitation Training on Cognitive Function in Parkinson's Disease with Subjective Cognitive Decline.Neuropsychiatric disease and treatment · 2024Article
- Assessment tools for cognitive performance in Parkinson's disease and its genetic contributors.Frontiers in neurology · 2024Article
- Genetic Insights into the Molecular Pathophysiology of Depression in Parkinson's Disease.Medicina (Kaunas, Lithuania) · 2023Review
- Aldehyde dehydrogenase 2 polymorphism is associated with chemotherapy-related cognitive impairment in patients with breast cancer who receive chemotherapy.Cancer medicine · 2023Article
- Investigating the interaction between neuropsychiatry features and daily activities on social function in patients with Parkinson's disease with mild cognitive impairment.BJPsych open · 2022Article
- Aldehyde Dehydrogenase 2 as a Therapeutic Target in Oxidative Stress-Related Diseases: Post-Translational Modifications Deserve More Attention.International journal of molecular sciences · 2022Review
- A commentary on the paper: 'Evaluation of spice and herb as phytoderived selective modulators of human retinaldehyde dehydrogenases using a simple in vitro method'.Bioscience reports · 2022Article
- Mild cognitive impairment in patients with Parkinson's disease: An updated mini-review and future outlook.Frontiers in aging neuroscience · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
(1) Background: Monoamine neurotransmitters play essential roles in the normal functioning of our nervous system. However, the metabolism of monoamine neurotransmitters is accompanied by the production of neurotoxic metabolites, and inefficient removal of the metabolites has been suggested to cause neurodegeneration. (2) Methods: To examine the effect of reduced activity of catechol-O-methyltransferase (COMT) and aldehyde dehydrogenase 2 (ALDH2) conferred by single nucleotide polymorphisms COMT rs4680(A) and ALDH2 rs671(A) on the symptoms of patients with Parkinson's disease (PD), a total of 114 PD patients were recruited cross-sectionally and received genotyping for rs4680 and rs671 along with MDS-UPDRS evaluation. (3) Results: We found that patients carrying rs4680(A) had more severe bradykinesia in the upper extremity and rest tremor. Besides, patients carrying rs671(A) had more difficulty maintaining personal hygiene, while patients with genotype rs671(GG) had higher scores in the item "depressed mood." More importantly, we found the effect of rs4680 to be moderated by rs671 SNP for the symptom of "hand movements." The detrimental impact of rs4680(A) is more pronounced in the presence of genotype rs671(GG). (4) Conclusions: This study facilitates a deeper understanding of the detrimental effect of reduced activity of COMT and ALDH2 conferred by genetic variation and provides novel insight into the interactions between enzymes metabolizing monoamine neurotransmitters in the pathogenesis of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.